Research Topics
| M M ReganSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trialMeredith M Regan
IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA
J Natl Cancer Inst 104:441-51. 2012..Cytochrome P450 2D6 (CYP2D6) enzyme metabolizes tamoxifen to clinically active metabolites, and CYP2D6 polymorphisms may adversely affect tamoxifen efficacy. In this study, we investigated the clinical relevance of CYP2D6 polymorphisms...
Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assaysMeredith M Regan
IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
J Natl Cancer Inst 98:1571-81. 2006..ER-positive premenopausal patients required further study...- Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trialsM M Regan
Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Ann Oncol 21:312-8. 2010..We investigated whether there is a subset of patients with CRPC for whom the efficacy of combination taxane-estramustine-carboplatin (TEC) chemotherapy may be greatest... - Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancerMeredith M Regan
International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA
Breast Cancer Res 13:209. 2011..Reports of BIG 1-98 should be interpreted in relation to each individual patient as she weighs the costs and benefits of available treatments. Clinicaltrials.gov ID: NCT00004205... 
Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?M M Regan
IBCSG Statistical Center, Dana Farber Cancer Institute, Harvard School of Public Health, Boston, MA, USA
Ann Oncol 19:1231-41. 2008..PERCHE closed with inadequate accrual; TEXT accrued rapidly...- Using clinical trial data to tailor adjuvant treatments for individual patientsMeredith M Regan
IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Breast 16:S98-104. 2007..Overview analyses, joint analyses, the STEPP (subpopulation treatment effect pattern plot) method and recursive partitioning are valuable tools... - Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-upMeredith M Regan
International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA
Lancet Oncol 12:1101-8. 2011..Therefore, trials assessing endocrine therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8·1 years median follow-up... - Predicting response to systemic treatments: learning from the past to plan for the futureMeredith M Regan
IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Breast 14:582-93. 2005..All findings from clinical trials and meta-analyses should be presented primarily according to steroid hormone receptor status and future studies should be designed as tailored treatment investigations... - Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancerAnita Giobbie-Hurder
International Breast Cancer Study Group Statistical Center, Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Clin Trials 6:272-87. 2009..Aromatase inhibitors provide superior disease control when compared with tamoxifen as adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer... - Phase II study of sunitinib in men with advanced prostate cancerM Dror Michaelson
Division of Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
Ann Oncol 20:913-20. 2009..This study explored the efficacy and tolerability of sunitinib, an inhibitor of tyrosine kinase receptors, in men with castration-resistant prostate cancer (CRPC)... - Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapyTimothy J Daskivich
Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Urology 70:527-31. 2007..To investigate whether the prostate-specific antigen doubling time (PSADT) and velocity (PSAV) at the emergence of androgen-independent prostate cancer (AIPC) provide independent prognostic information... - Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancerDaniel J George
Lank Center for Genitourinary Oncology, Division of Solid Tumor Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Urology 63:327-32. 2004..CONCLUSIONS: These results suggest that the prostate gland itself may be a significant source of systemic VEGF and raises the possibility that elevated plasma VEGF levels could be a reflection of prostatic VEGF production... - Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancerMary Ellen Taplin
Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 24:5408-13. 2006..The purpose of this trial was to determine the feasibility, toxicity, and prostate-specific antigen (PSA) response of chemotherapy and limited ADT for men with PSA relapse... - Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancerMari Nakabayashi
Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer 107:975-81. 2006..Although uncommon, additional durable responses occurred in some patients after dose escalation... - Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphataseWanling Xie
Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer 110:2709-15. 2007..In the current study, the authors evaluated the combined effects of PSA and ALK-P on survival... - Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostateM-H Tay
Lank Center for Genitourinary Oncology, Division of Solid Tumor Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Ann Oncol 15:974-8. 2004..CONCLUSION: Finasteride provides additional intracellular androgen blockade when added to bicalutamide. Duration of control is comparable to castration, with preserved sexual function in some patients... - Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancerMari Nakabayashi
Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
BJU Int 105:1392-6. 2010.... - Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancerRobert W Ross
Dana Farber Cancer Institute, Dana 710 C, 44 Binney St, Boston, MA 02115, USA
J Clin Oncol 26:842-7. 2008..Androgen-deprivation therapy (ADT) is the most common and effective systemic therapy for advanced prostate cancer. We hypothesized that germline genetic variation in the androgen axis would improve the efficacy of ADT... - Variability of viral load in plasma of rhesus monkeys inoculated with simian immunodeficiency virus or simian-human immunodeficiency virus: implications for using nonhuman primate AIDS models to test vaccines and therapeuticsR A Parker
Biometrics Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
J Virol 75:11234-8. 2001..Thus, differences in VL variability over the course of infection and between viruses need to be considered when designing studies using the nonhuman primate AIDS models... - Regression models and risk estimation for mixed discrete and continuous outcomes in developmental toxicologyM M Regan
Biometrics Center, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Risk Anal 20:363-76. 2000..Dose-response models and their application to quantitative risk assessment are illustrated using data from a recent developmental toxicology experiment of ethylene oxide in mice... - Likelihood models for clustered binary and continuous outcomes: application to developmental toxicologyM M Regan
Biometrics Center E GZ 800, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Biometrics 55:760-8. 1999..The joint risk of malformation and low birth weight can then be estimated directly. This approach is particularly well suited to estimating safe dose levels as part of quantitative risk assessment... - Gender bias in the disposition of frozen embryosS Klipstein
Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Fertil Steril 76:1181-4. 2001..To examine the gender differences found among couples when choosing the disposition of their frozen embryos... - Long-term psychosocial adjustment of older vs younger survivors of breast and endometrial cancerAlice B Kornblith
Breast Oncology Program Mayer 2, Dana Farber Cancer Institute, Boston, MA 02115, USA
Psychooncology 16:895-903. 2007..The study's objective was to test whether there were signfiicant differences in adjustment between younger and older breast and endometrial cancer survivors... - Cancer-related communication between female patients and male partners scale: A pilot studyAlice B Kornblith
Women s Cancers Program D 1210, Dana Farber Cancer Institute, Boston, MA 02115, USA
Psychooncology 15:780-94. 2006.... - Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinomaDaniel C Cho
Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
J Immunother 32:181-5. 2009..The assumption that IL-2 therapy can be safely administered after TKI therapy may not be valid. Further examination of the safety of this sequential approach is necessary and more cautious patient selection seems warranted... - Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancerMari Nakabayashi
Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
BJU Int 101:308-12. 2008..To evaluate the efficacy of docetaxel/carboplatin (DC)-based chemotherapy as first- and second-line chemotherapy for patients with hormone-refractory prostate cancer (HRPC)... - Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effectRobert W Ross
Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer 112:1247-53. 2008..The purpose of this study was to compare predictive factors for the efficacy of androgen deprivation therapy (ADT) in men with hormone-sensitive prostate cancer (HSPC) either with (M+) or without (M-) metastases... - Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapyToni K Choueiri
Dana Farber Harvard Cancer Center, Boston, MA, USA
BJU Int 106:772-8. 2010.... - Physicians' experiences with BRCA1/2 testing in community settingsNancy L Keating
Division of General Internal Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
J Clin Oncol 26:5789-96. 2008.... - Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapyToni K Choueiri
Dana Farber Cancer Institute Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
Cancer 115:981-7. 2009.... - Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigenIgnacio F San Francisco
Division of Urologic Surgery and Biometrics Center (MMR, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
J Urol 171:1492-9. 2004..These 3 predictors are displayed in a nomogram-type format to summarize estimated 5 and 10-year recurrence-free probabilities... - Association of cystic fibrosis with abnormalities in fatty acid metabolismSteven D Freedman
Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
N Engl J Med 350:560-9. 2004..In this study we determined whether humans with mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene have a similar fatty acid defect in tissues expressing CFTR... - Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitisSunil Sheth
Department of Medicine, Beth Israel Deaconess Medical Center Harvard Medical School, Dana 532, 330 Brookline Avenue, Boston, MA 02215, USA
Hum Genet 113:286-92. 2003.... - Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factorsSharon L Bober
David B Perini Quality of Life Clinic, D321, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
J Clin Oncol 22:4951-7. 2004..To explore the health-related and psychological factors that influence decision making about tamoxifen (Nolvadex; AstraZeneca, Waltham, MA) chemoprevention in women at increased risk for developing breast cancer... - Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaDavid F McDermott
Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, E KS 153, Boston, MA 02215, USA
J Clin Oncol 23:133-41. 2005..The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma... - Physician attitudes toward cytotoxic chemotherapy use in patients with advanced prostate carcinomaWilliam K Oh
Lank Center for Genitourinary Oncology, Department of Adult Oncology, Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer 97:2171-9. 2003..This is important as randomized trials using chemotherapy are proposed. The authors used a questionnaire to investigate the attitudes of physicians in the New England area who care for patients with advanced prostate carcinoma... - Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trialsDavid F McDermott
Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Clin Genitourin Cancer 5:114-9. 2006..This year, investigators will launch a clinical trial designed to prospectively determine whether patients who are more likely to respond to high-dose IL-2 can be identified before therapy is initiated... - Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancerMari Nakabayashi
Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Haber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
BJU Int 96:783-6. 2005..CONCLUSIONS: Nilutamide appears to be an effective secondary hormonal therapy in patients with AIPC and is associated with a mild toxicity profile... - Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancerIgnacio F San Francisco
Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
J Urol 175:1341-5; discussion 1345-6. 2006..5 ng/dl or less, or by age adjusted free T (p = 0.017 and 0.04, respectively). CONCLUSIONS: Low age adjusted free T as well as single cutoff free T correlates with poorly differentiated prostate cancer in surgically treated patients... - Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomyGlenn J Bubley
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
J Urol 168:2249-52. 2002..In fact, it is possible that altered levels of these proteins observed in subjects at risk for prostate cancer are the result of prostate cancer rather than related to its cause... - Echocardiographic predictors of left ventricular outflow tract obstruction and systolic anterior motion of the mitral valve after mitral valve reconstruction for myxomatous valve diseaseA D Maslow
Department of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
J Am Coll Cardiol 34:2096-104. 1999..To determine predictors of systolic anterior motion and left ventricular outflow tract obstruction (SAM/LVOTO) after mitral valve repair (MVRep) in patients with myxomatous mitral valve disease... - Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patientsDimitrios Spentzos
Divisions of Hematology/Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
Clin Cancer Res 9:3282-7. 2003..The addition of soy protein had a modest effect on TTP. A potentially undesirable effect associated with the administration of soy was an increase in IGF-I serum levels... - Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United StatesJuan Miguel Mosquera
Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Clin Cancer Res 15:4706-11. 2009..We sought to determine the prevalence of TMPRSS2-ERG gene fusion among prostate-specific antigen-screened men undergoing prostate biopsy in the United States... - Relationship between serum adiponectin and prostate cancer gradeDavid J Sher
Harvard Radiation Oncology Program, Boston, Massachusetts 02115, USA
Prostate 68:1592-8. 2008..We evaluated the relationship between serum adiponectin and Gleason score (GS) in a prospective series of patients seen in a single institution... - Evaluation of the 8q24 prostate cancer risk locus and MYC expressionMark M Pomerantz
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Cancer Res 69:5568-74. 2009..These data will help to direct the future study of this risk locus... - Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancerMari Nakabayashi
Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Cancer J 13:125-9. 2007..However, little is known about the efficacy of VRL as second-line chemotherapy in HRPC... - The relationship of prostate gland volume to extended needle biopsy on prostate cancer detectionJean O Ung
Department of Urologic Surgery and Biometrics Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
J Urol 169:130-5. 2003..Increased serum PSA levels in cases of larger prostates, although a risk factor for prostate cancer warranting biopsy, may also be due to nonmalignant sources such as benign prostatic hyperplasia... - Analysis of cystic fibrosis gener product (CFTR) function in patients with pancreas divisum and recurrent acute pancreatitisAndres Gelrud
Division of Gastroenterology and Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
Am J Gastroenterol 99:1557-62. 2004.... - Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is alteredMunir M Zaman
Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
Clin Diagn Lab Immunol 11:819-24. 2004..This is not a result of increased LPS receptor expression but, rather, is associated with alterations in MAPK signaling... - Inhaled albuterol, but not intravenous lidocaine, protects against intubation-induced bronchoconstriction in asthmaA D Maslow
Department of Anesthesia, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Anesthesiology 93:1198-204. 2000.... - Preoperative serum acid phosphatase and alkaline phosphatase are not predictors of pathological stage and prostate-specific antigen failure after radical prostatectomyI F San Francisco
Division of Urologic Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
BJU Int 92:924-8. 2003..CONCLUSIONS: Preoperative enzymatic serum TAP, PFAP and ALP levels are not predictors of the severity of disease or PSA disease-free recurrence after RRP... - 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYCNasim Ahmadiyeh
Department of Medical Oncology, Dana Farber Cancer Institute, Boston MA 02115, USA
Proc Natl Acad Sci U S A 107:9742-6. 2010..We therefore propose that the 8q24 risk loci operate through a common mechanism-as tissue-specific enhancers of MYC... - Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancerQianben Wang
Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
Cell 138:245-56. 2009..Thus, the role of AR in androgen-independent cancer cells is not to direct the androgen-dependent gene expression program without androgen, but rather to execute a distinct program resulting in androgen-independent growth... - Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detectionStephen J Eyre
Division of Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 20015, USA
J Urol 182:2653-8. 2009..We assessed the generalizability of the Prostate Cancer Prevention Trial calculator in a cohort more representative of patients referred for consideration of prostate biopsy in American urology practice... - Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4Timothy J Daskivich
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
J Urol 176:1927-37. 2006..Clinicians and researchers should understand how methodological differences influence the value of calculated prostate specific antigen doubling time for purposes of patient care and research... - Absence of relationship between steroid hormone levels and prostate cancer tumor gradeDavid J Sher
Harvard Radiation Oncology Program, Boston, Massachusetts, USA
Urology 73:356-61; discussion 361-2. 2009..To analyze the relationship between plasma testosterone and estradiol levels on prostate biopsy and radical prostatectomy Gleason scores in a cohort of patients with newly diagnosed prostate cancer... - Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancerMary Ellen Taplin
Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02115, USA
Clin Cancer Res 15:7099-105. 2009.... - The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancerMark M Pomerantz
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
Nat Genet 41:882-4. 2009..These data provide strong support for a biological mechanism underlying this non-protein-coding risk variant... - Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study GroupGiuseppe Viale
Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
J Clin Oncol 26:1404-10. 2008.... - Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancerGiuseppe Viale
Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Via Ripamoniti 435, Milan, Italy
J Natl Cancer Inst 100:207-12. 2008..Thus, Ki-67 labeling index was an independent prognostic factor but was not predictive of better response to adjuvant chemotherapy in these studies... - Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trialBirgitte B Rasmussen
Department of Pathology, Nordsjaellands Hospital, Hilleroed, Denmark
Lancet Oncol 9:23-8. 2008..Our aim was to establish whether the benefit of letrozole versus tamoxifen differs according to the ERBB2 status of tumours... - Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98Giuseppe Viale
Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
J Clin Oncol 25:3846-52. 2007..To evaluate locally versus centrally assessed estrogen (ER) and progesterone (PgR) receptor status and the impact of PgR on letrozole adjuvant therapy compared with tamoxifen in postmenopausal women with early breast cancer... - Survey of breast-feeding practices and outcomes in the cystic fibrosis populationEliza M Parker
Department of Pediatrics, University of Massachusetts Medical School and UMass Memorial Health Care, Worcester, Massachusetts 01655, USA
Pediatr Pulmonol 37:362-7. 2004..This survey indicates that breast-feeding is not harmful to children with CF, and may be beneficial... - Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling timePhilip M Arlen
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
J Urol 179:2181-5; discussion 2185-6. 2008..It is important to agree on definitions and values for the calculation of prostate specific antigen doubling time, and to develop a common approach to outcome analysis and reporting... - Lysine requirements of healthy adult Indian subjects receiving long-term feeding, measured with a 24-h indicator amino acid oxidation and balance techniqueAnura V Kurpad
Department of Physiology and Nutrition Research Center, St John s Medical College, Bangalore, India
Am J Clin Nutr 76:404-12. 2002..The mean lysine requirement of healthy Indian subjects was estimated from short-term experimental diet periods to be 29 mg x kg(-1) x d(-1), which is higher than the 1985 FAO/WHO/UNU upper requirement of 12 mg x kg(-1) x d(-1)... - Intravenously infused 13C-leucine is retained in fasting healthy adult menAnura V Kurpad
Department of Physiology and Division of Nutrition, St. John's Medical College, Bangalore, India
J Nutr 132:1906-8. 2002..We conclude that tracer leucine infused in the fasting state does not measurably increase leucine oxidation at the doses studied. Thus, tracer intake during the 12-h fast contributes to the effective leucine intake in 24-h DAAB studies...